Changes of Proteases, Antiproteases, and Pathogens in Cystic Fibrosis Patients’ Upper and Lower Airways after IV-Antibiotic Therapy
Table 5
Inflammation markers and ratios in controls and CF patients before and after IV-AB treatment.
Inflammatory marker or ratio concentrations
Analyte
DL
Detection frequency (%)
Median
Range
P
Controls
CF prior to therapy
CF after therapy
Controls
CF prior to therapy
CF after therapy
Controls
CF prior to therapy
CF after therapy
NL (UAW)
NE (ng/mL)
1.98
100.0
89.5
100.0
1.7
73.4
55.6
0.2–38.0
2.3–990.0
2.3–233.6
0.374* 0.0000°
SLPI (ng/mL)
0.01
30.0
10.5
21.1
0.01
0.01
0.01
0.01–0.06
0.01–0.17
0.01–0.15
1.000* 0.235°
CTSS (ng/mL)
0.07
85.0
5.3
21.1
0.04
0.07
0.07
0.00–0.24
0.07–0.14
0.07–1.08
0.125* 0.0004°
MMP-9 (ng/mL)
0.04
100.0
100.0
0.9
0.32
0.02–7.8
0.04–3.96
0.106*
TIMP-1 (ng/mL)
0.01
100.0
100.0
1.8
1.7
0.4–4.2
0.01–2.9
0.036*
MMP-9/TIMP1
n.m.
100.0
89.5
n.m.
0.38
0.20
n.m.
0.0–2.3
0.03–17.0
0.359*
NE/SLPI
100.0
10.5
21.1
91.7
919.1
658.1
16.9–780.1
791.0–1047.1
301.8–2510.8
n.mb.
SLPI/CTSS
—
—
—
—
—
—
—
—
—
Sputum (LAW)
NE (ng/mL)
1.98
61.5
81.3
328.8
697.4
2.3–2366.5
2.3–17987.2
0.791*
SLPI (ng/mL)
0.01
38.5
62.5
0.01
133.4
0.01–383.6
0.01–487.9
0.432*
CTSS (ng/mL)
0.07
100.0
93.8
3.3
4.7
0.7–63.8
0.1–33.9
0.376
MMP-9 (ng/mL)
0.04
100.0
100.0
1359.7
1195.9
1063.2–1848.0
153.5–1417.5
0.017*
TIMP-1 (ng/mL)
100.0
100.0
50.7
66.0
7.5–134.2
0.14–480.8
0.191*
MMP-9/TIMP1
100.0
93.8
26.1
17.4
7.9–181.8
2.0–62.2
0.094*
NE/SLPI
23.1
50.0
3.0
4.9
0.7–7.1
0.5–50.2
n.mb.
SLPI/CTSS
38.5
62.5
60.6
37.3
3.4–117.9
3.4–71.3
1.000*
*P value between CF prior to and after therapy, °P value between CF prior to therapy and healthy controls in UAW, DL = detection limit, n.m. = not measured, and n.mb. = not measureable.
